Novel aldose reductase inhibitors: a patent survey (2006 – present)
| Autor: | Polyxeni Alexiou, Maria Chatzopoulou, Vassilis J. Demopoulos, Eleni Kotsampasakou |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pharmacology
Aldose reductase Molecular Structure Protein Conformation business.industry Anti-Inflammatory Agents Cancer Antineoplastic Agents General Medicine Bioinformatics medicine.disease Patents as Topic Structure-Activity Relationship Biochemistry Aldehyde Reductase Drug Design Expert opinion Drug Discovery Animals Humans Hypoglycemic Agents Medicine Enzyme Inhibitors business |
| Zdroj: | Expert Opinion on Therapeutic Patents. 22:1303-1323 |
| ISSN: | 1744-7674 1354-3776 |
| Popis: | Initially studied for its central role in the pathogenesis of chronic diabetic complications, aldose reductase (ALR2) gains more attention over the years as its implication in inflammatory diseases is being established, along with the therapeutic potential of its inhibitors.Reviewing the patents that were published since 2006, it is getting clear that the search for new chemical entities has subsided, giving rise to natural products and plant extracts with ALR2 inhibitory activity. Other aspects that were prominent were the search for proper forms of known inhibitors, in a way to improve their impaired physicochemical profile, as well as potential combination therapies with other compounds of pharmaceutical interest. On the spotlight were patents enhancing the therapeutic usage of aldose reductase inhibitors (ARIs) to various pathological conditions including cancer and inflammation-mediated diseases such as sepsis, asthma, and cancer.Although new chemical entities are scarcely registered and patented after many years of inconclusive clinical trials, the involvement of ALR2 to inflammatory pathologies might renew the interest in the field of ARIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|